REPATHA SYRINGE (evolocumab)
HYPERCHOLESTEROLEMIA·+3
AMGEN
Indication
Increased cardiovascular event risk
Increased cardiovascular event risk refers to a heightened susceptibility to major adverse cardiovascular outcomes, such as myocardial infarction, ischemic stroke, and cardiovascular death, within the circulatory system. Read more about Increased cardiovascular event risk
3 drugs 2 manufacturers
Drugs that treat it
Common Increased cardiovascular event risk therapies.
REPATHA SURECLICK (evolocumab)
ANTIHYPERLIPIDEMIC - PCSK9 INHIBITORS·HYPERCHOLESTEROLEMIA·+3
AMGEN USA INC.
REPATHA SYRINGE (evolocumab)
ANTIHYPERLIPIDEMIC - PCSK9 INHIBITORS·HYPERCHOLESTEROLEMIA·+3
AMGEN USA INC.
Filter & compare in the drug finder →Opens the drug finder with Increased cardiovascular event risk preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonIncreased cardiovascular event risk refers to a heightened susceptibility to major adverse cardiovascular outcomes, such as myocardial infarction, ischemic stroke, and cardiovascular death, within the circulatory system.
Rather than representing an isolated, discrete disease entity, it is a clinical risk stratification state commonly identified in patient populations with established atherosclerotic cardiovascular disease, type 2 diabetes mellitus, chronic kidney disease, hypertension, or advanced metabolic risk factors.
Pathophysiologically, it is driven by systemic endothelial dysfunction, chronic vascular inflammation, lipid accumulation, and progressive atherothrombotic plaque development that predispose arterial beds to rupture, occlusion, and tissue ischemia.
Regulatory agencies and professional guidelines use this designation to qualify high-risk individuals for preventive pharmacological therapies aimed at reducing secondary or primary cardiovascular morbidity and mortality.
- fda.gov
Increased cardiovascular event risk refers to a heightened susceptibility to major adverse cardiovascular outcomes, such as myocardial infarction, ischemic stroke, and cardiovascular death, within the circulatory system Rather than representing an isolated, discrete disease entity, it is a clinical risk stratification state commonly identified in patient populations with established atherosclerotic cardiovascular disease, type 2 diabetes mellitus, chronic kidney disease, hypertension, or advance...
- fda.gov
Increased cardiovascular event risk refers to a heightened susceptibility to major adverse cardiovascular outcomes, such as myocardial infarction, ischemic stroke, and cardiovascular death, within the circulatory system Rather than representing an isolated, discrete disease entity, it is a clinical risk stratification state commonly identified in patient populations with established atherosclerotic cardiovascular disease, type 2 diabetes mellitus, chronic kidney disease, hypertension, or advance...
- mdcalc.com
Increased cardiovascular event risk refers to a heightened susceptibility to major adverse cardiovascular outcomes, such as myocardial infarction, ischemic stroke, and cardiovascular death, within the circulatory system Pathophysiologically, it is driven by systemic endothelial dysfunction, chronic vascular inflammation, lipid accumulation, and progressive atherothrombotic plaque development that predispose arterial beds to rupture, occlusion, and tissue ischemia
- fda.gov
Rather than representing an isolated, discrete disease entity, it is a clinical risk stratification state commonly identified in patient populations with established atherosclerotic cardiovascular disease, type 2 diabetes mellitus, chronic kidney disease, hypertension, or advanced metabolic risk factors
- heart.org
Rather than representing an isolated, discrete disease entity, it is a clinical risk stratification state commonly identified in patient populations with established atherosclerotic cardiovascular disease, type 2 diabetes mellitus, chronic kidney disease, hypertension, or advanced metabolic risk factors
- nih.gov
Regulatory agencies and professional guidelines use this designation to qualify high-risk individuals for preventive pharmacological therapies aimed at reducing secondary or primary cardiovascular morbidity and mortality
- nih.gov
Regulatory agencies and professional guidelines use this designation to qualify high-risk individuals for preventive pharmacological therapies aimed at reducing secondary or primary cardiovascular morbidity and mortality
Personalize your experience
Follow Increased cardiovascular event risk and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.